| Date Filed | Type | Description |
| 02/17/2009 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2009 |
SC 13G/A
| RENAISSANCE TECHNOLOGIES LLC reports a 0% stake in RENOVIS, INC. |
| 02/09/2009 |
SC 13G/A
| DIMENSIONAL FUND ADVISORS INC reports a 0% stake in RENOVIS INC |
| 05/02/2008 |
8-K
| Quarterly results |
| 05/01/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 05/01/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/29/2008 |
SC 13G
| MMCAP International Inc. SPC reports a 10% stake in Renovis, Inc. |
| 04/25/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 04/25/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/22/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 04/22/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/18/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 04/18/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/16/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 04/03/2008 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/03/2008 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Renovis Announces Expiration of Hart-Scott-Rodino 30-Day Waiting Period; Merger with Evotec On Track to Close In Early May, 2008 South San Francisco, California - April 3, 2008 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired without the United States Federal Trade Commission requesting additional information with regard to the pending acquisition of Renovis by Evotec AG . The companies anticipate that the transaction, which remains subject to the approval of Renovis's stockholders and other customary closing conditions, will close in earl..." |
|
| 03/28/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 03/28/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 03/26/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 03/26/2008 |
8-K
| Other Events |
| 03/25/2008 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 03/17/2008 |
10-K
| Annual Report for the period ended December 31, 2007 |
| 03/14/2008 |
8-K
| Quarterly results|
Docs:
|
"RENOVIS REPORTS FOURTH QUARTER AND FULL YEAR 2007 FINANCIAL RESULTS South San Francisco, California - March 14, 2008 - Renovis, Inc. , a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced financial results for the fourth quarter and year ended December 31, 2007. Revenue for the fourth quarter and the year ended December 31, 2007 was $1.3 million and $9.8 million, respectively, compared to $2.2 million and $10.4 million in the corresponding periods in 2006. All of the revenue earned in the year ended December 31, 2007 related to our collaboration with Pfizer Inc. to research, develop and commercialize small molecules that target the vanilloid receptor, or VR1. The decreas..." |
|
| 03/11/2008 |
SC 13G
| MMCAP International Inc. SPC reports a 11.4% stake in Renovis, Inc. |
| 02/14/2008 |
SC 13G/A
| GREAT POINT PARTNERS LLC reports a 5.3% stake in RENOVIS, INC. |
| 02/14/2008 |
SC 13G/A
| RA CAPITAL MANAGEMENT, LLC reports a 0% stake in RENOVIS, INC. |
| 02/14/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 02/13/2008 |
SC 13G
| RENAISSANCE TECHNOLOGIES LLC reports a 5.1% stake in RENOVIS, INC. |
| 02/11/2008 |
SC 13G/A
| MKM LONGBOAT CAPITAL ADVISORS LLP reports a 5.7% stake in Renovis, Inc. |
| 02/06/2008 |
SC 13G
| DIMENSIONAL FUND ADVISORS INC reports a 6.2% stake in RENOVIS INC |
| 02/05/2008 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/01/2008 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 9% stake in Renovis, Inc. |
| 01/11/2008 |
8-K
| Other Events |
| 01/10/2008 |
425
| Form 425 - Prospectuses and communications, business combinations |
|